Skip to main content
C
CorpDigest
Search

Merck & Co., Inc.

Pharmaceuticals / Biotechnology / Animal HealthFounded 1891
Reviewed by Swet Parvadiya
Company data updated: October 2026

Leadership History

Merck: CEO History

5 leaders · 1985 to present

Who is the CEO of Merck?

Robert M. Davis is the CEO of Merck, in the role since 2021. The first chief executive was P. Roy Vagelos, from 1985.

Current CEO
Robert M. Davis (since 2021)
First CEO
P. Roy Vagelos (1985)
Leaders documented
5
Founded
1891
NameRoleFromToYears in role
Robert M. DavisChairman and CEO2021Present5
Kenneth FrazierChairman and CEO2011202110
Richard T. ClarkChairman and Chief Executive Officer200520105
Raymond V. GilmartinChairman and Chief Executive Officer1994200511
P. Roy VagelosChairman and CEO198519949
Who was CEO of Merck before Robert M. Davis?
Kenneth Frazier was CEO of Merck from 2011 to 2021, before Robert M. Davis took over in 2021.

Company Overview

Merck & Co. is one of the largest U.S. pharmaceutical companies by sales, with $65.0 billion in 2025 revenue, about 75,000 employees and a market value near $368 billion in late September 2026. It researches, makes and sells cancer drugs, vaccines, cardiovascular and infectious-disease medicines, and animal health products in more than 140 markets. Keytruda, its PD-1 cancer immunotherapy, was the world's top-selling drug brand in 2025 and drives about half of company sales, so the company's current agenda centers on replacing that revenue before U.S. patent protection begins to lapse in 2028. The company is headquartered in Rahway, New Jersey.

Robert M. Davis

Chairman and CEO

2021 – Present

5 years (current)

Key Decisions & Impact

Rob Davis inherited the Keytruda franchise at peak growth and faces the defining challenge of his tenure: preparing Merck for Keytruda's patent expiration (2028 in the US). He has pursued aggressive business development acquiring Acceleron ($11.5B), Prometheus ($10.8B), and numerous smaller pipeline assets while investing in subcutaneous Keytruda formulations and next-generation immuno-oncology combinations to extend the franchise beyond patent expiry. Davis took over in July 2021, shortly after the June 2021 Organon spin-off, and has continued to expand the animal health business.

Legacy

Since 2025 has added Verona Pharma, Cidara Therapeutics and Terns Pharmaceuticals, launched Keytruda Qlex and won 2026 FDA approval for oral PCSK9 inhibitor Lipfendra, while guiding to $66.3 billion to $67.3 billion in 2026 sales.

Source →

Kenneth Frazier

Chairman and CEO

2011 – 2021

10 years

Key Decisions & Impact

Kenneth Frazier navigated Merck through patent cliffs and rebuilt the company around Keytruda (pembrolizumab), which grew from a niche melanoma drug into the world's best-selling medicine at $25+ billion annually. His decision to persist with the Keytruda clinical program expanding into dozens of cancer types and combination regimens proved transformative. Frazier also stewarded Merck's COVID-19 antiviral (molnupiravir) development and maintained R&D investment discipline during periods when cost-cutting would have been easier. He was the first African American to lead a major pharmaceutical company.

Legacy

Backed the broad Keytruda development program that made it Merck's dominant product and oversaw the 2021 Organon spin-off planning.

Source →

Richard T. Clark

Chairman and Chief Executive Officer

2005 – 2010

5 years

Key Decisions & Impact

Clark became chief executive in 2005 after the withdrawal of Vioxx and settled the resulting litigation for $4.85 billion.

Legacy

He led the 2009 purchase of Schering-Plough. Kenneth Frazier succeeded him at the start of 2011.

Source →

Raymond V. Gilmartin

Chairman and Chief Executive Officer

1994 – 2005

11 years

Key Decisions & Impact

Gilmartin became the first outsider to lead Merck in 1994.

Legacy

He launched Vioxx and Singulair and withdrew Vioxx in 2004. Richard Clark succeeded him in 2005.

Source →

P. Roy Vagelos

Chairman and CEO

1985 – 1994

9 years

Key Decisions & Impact

Roy Vagelos led Merck during its golden era of blockbuster drug discovery. A former head of Merck Research Labs, he oversaw the development of Mevacor (first statin approved for cholesterol), Vasotec (ACE inhibitor), Proscar (BPH), and Mectizan (ivermectin for river blindness). His decision to donate Mectizan for free to every person who needed it in the developing world indefinitely remains one of the most celebrated acts of corporate philanthropy in pharmaceutical history. Vagelos proved that research excellence and commercial success could coexist.

Legacy

Turned Merck Research Laboratories into the engine behind Mevacor and Vasotec and launched the Mectizan Donation Program in 1987.

Source →

Challenges & Strategic Context

Merck's main challenge is concentration: Keytruda supplied about 49% of 2025 sales, and its key U.S. patent protection begins to expire in 2028, opening the door to biosimilar pembrolizumab. Gardasil sales fell 39% to $5.2 billion in 2025 after demand in China collapsed, showing how one government's procurement decisions can move billions in revenue. U.S. pricing policy is a second pressure point: Januvia's Medicare negotiated price took effect in January 2026, and broader Inflation Reduction Act negotiation could reach other large products. Pipeline risk is the third. Merck spent roughly $26 billion buying Verona Pharma, Cidara Therapeutics and Terns Pharmaceuticals between October 2025 and mid-2026, and those deals only pay off if Ohtuvayre, the long-acting flu preventive CD388 and the CML drug MK-4208 reach their commercial potential. Acquisition charges also hit earnings, including a $2.31-per-share charge for Terns that pushed Merck to a GAAP loss in Q2 2026.

Merck CEO and Leadership FAQ

Who was Dr. P. Roy Vagelos and what was his scientific legacy as Merck CEO?

Dr. P. Roy Vagelos, a physician and biochemist, served as CEO of Merck from 1985 to 1994. Vagelos transformed Merck into a scientific leader, leading the discovery and launch of blockbuster cholesterol statin Mevacor (lovastatin), Vasotec for hypertension, and establishing the historic Mectizan river blindness donation program.

What was Kenneth C. Frazier's historic leadership tenure at Merck from 2011 to 2021?

Kenneth C. Frazier served as CEO and Chairman from 2011 to 2021, becoming one of America's most prominent African American Fortune 500 chief executives. Frazier boldly prioritized high-risk cancer immunotherapy research, greenlighting Keytruda's large clinical development program and executing the spin-off of Organon.

What strategic priorities define Robert M. Davis' leadership as CEO since 2021?

Since becoming CEO in July 2021, Robert M. Davis has focused on aggressive business development to diversify beyond Keytruda: orchestrating the $11.5B acquisition of Acceleron (Winrevair), the $10.8B acquisition of Prometheus (immunology), the $22B Daiichi Sankyo ADC alliance, and modernizing the Rahway global headquarters.

How did Kenneth Frazier handle the Vioxx recall and legal defense in the 2000s?

When arthritis painkiller Vioxx was voluntarily withdrawn in 2004 due to cardiovascular risks, Ken Frazier (then Merck's General Counsel) executed a well-known legal defense strategy: rejecting class-action settlements to try individual cases in court, winning the vast majority, and settling remaining claims for a manageable $4.85 billion in 2007.

Who was George W. Merck and how did he lead the company during World War II?

George W. Merck led the company from 1925 to 1950, steering the mass industrialization of penicillin during World War II, establishing Merck Research Laboratories, and establishing the corporate philosophy that prioritizing patient health ultimately drives enduring corporate profits.

Who was Raymond Gilmartin and what major merger did Richard Clark execute?

Raymond Gilmartin served as CEO from 1994 to 2005 during Vioxx's development, while successor Richard Clark (CEO 2005 to 2011) restructured the company and executed the transformative $41 billion merger with Schering-Plough in 2009, which brought Keytruda (then MK-3475) into Merck's pipeline.

Who serves as President of Merck Research Laboratories (MRL)?

Dr. Dean Y. Li serves as Executive Vice President and President of Merck Research Laboratories, leading over 10,000 scientists worldwide across discovery, preclinical pharmacology, translational medicine, and global clinical oncology trials.

How does Merck's executive board maintain scientific governance?

Merck's Board of Directors includes a dedicated Research Committee composed of distinguished physicians, Nobel laureates, and academic biomedical researchers who regularly review pipeline data, drug discovery targets, and clinical trial safety protocols.

Who was George W. Merck and what was his famous corporate creed?

George W. Merck served as president from 1925 to 1950 and chairman until 1957. In 1950, he articulated the legendary ethos that defines Merck: "We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear." This philosophy inspired Merck's decision to distribute the river blindness treatment Mectizan free of charge to developing nations indefinitely.

Related Leadership Timelines

Compare executive leadership tenures and strategic transitions

Competitor

Pfizer

View Leadership Timelines
Competitor

Eli Lilly

View Leadership Timelines
Competitor

Bristol Myers Squibb

View Leadership Timelines
Competitor

Astrazeneca

View Leadership Timelines
Competitor

Roche

View Leadership Timelines
Competitor

Johnson And Johnson

View Leadership Timelines

Explore Merck

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.